XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Additional Information (Details)
3 Months Ended 9 Months Ended
Oct. 03, 2021
USD ($)
Sep. 27, 2020
USD ($)
Agreement
Award
Oct. 03, 2021
USD ($)
Sep. 27, 2020
USD ($)
Apr. 16, 2021
USD ($)
Jan. 03, 2021
USD ($)
Disaggregation Of Revenue [Line Items]            
Contract asset $ 48,700,000   $ 48,700,000     $ 42,800,000
Credit losses related to contract assets 0 $ 0 0 $ 0    
Deferred revenue, current 32,600,000   32,600,000     35,500,000
Deferred revenue, revenue recognized     31,300,000      
Award received in connection with arbitration proceeding 8,500,000          
Revenue recognized 15,100,000 $ 7,000,000.0 27,800,000 14,700,000    
Other Assets            
Disaggregation Of Revenue [Line Items]            
Contract asset 800,000   800,000     2,400,000
Other Liabilities            
Disaggregation Of Revenue [Line Items]            
Deferred revenue, non-current 5,800,000   5,800,000     6,600,000
Customer Supply Agreement            
Disaggregation Of Revenue [Line Items]            
Contract asset 12,700,000   12,700,000     15,100,000
Customer Supply Agreement | Other Assets            
Disaggregation Of Revenue [Line Items]            
Contract asset 800,000   800,000     2,400,000
Contractual Arrangements            
Disaggregation Of Revenue [Line Items]            
Contract asset 36,000,000.0   36,000,000.0     24,300,000
Contract Manufacturing Agreements            
Disaggregation Of Revenue [Line Items]            
Contract asset           $ 3,400,000
Biomedical Advanced Research and Development Authority            
Disaggregation Of Revenue [Line Items]            
Number of collaboration and license agreements | Agreement   2        
Number of awards under collaboration and license agreements | Award   2        
Biomedical Advanced Research and Development Authority | Maximum            
Disaggregation Of Revenue [Line Items]            
Potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests   $ 13,600,000   13,600,000    
Additional awards granted, potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests         $ 3,600,000  
Biomedical Advanced Research and Development Authority | Grant Revenue            
Disaggregation Of Revenue [Line Items]            
Revenue recognized $ 1,500,000 $ 2,500,000 $ 7,300,000 $ 2,500,000